A New ACP3-Targeted PET/CT Scan to Find Prostate Cancer
Compares an ACP3-targeted PET/CT scan with standard scans for finding prostate cancer.
Plain-language title generated from the registry record
Registry title: Theranostic Applications of Radionuclides in Prostate Cancer
Key facts
- Where
- Guilin, ChinaSee the site
Where in China
- The First Affliated Hospital of Guilin Medical UniversityGuilin, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Guilin Medical University, China
- Trial code
- NCT07559201
- Record updated
- 30 April 2026
- Original description
The objective of the study is to construct a noninvasive approach ACP3 targeted PET/CT to detect tumor lesions in patients with prostate cancer and to compare with PSMA/FDG PET/CT.Read full original descriptionShow less
ACP3 Targeted -PET/ CT in Prostate Cancer
The objective of the study is to construct a noninvasive approach ACP3 targeted PET/CT to detect tumor lesions in patients with prostate cancer and to compare with PSMA/FDG PET/CT.
Inclusion: Adult patients (aged 18 years or older); Patients with newly diagnosed, highly suspected recurrence or previously treated metastases of prostate cancer (supporting evidence may include MRI, CT, tumor markers, and pathology report); Patients who had scheduled both standard-of-care imaging (PSMA/FDG PET/CT) and ACP3 PET/CT scans; Patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.
Exclusion: The inability or unwillingness of the research participant or legal representative to provide written informed consent.